Eligibility, uptake and response to germline genetic testing in women with DCIS

Eligibility, uptake and response to germline genetic testing in women with DCIS

BackgroundDuctal carcinoma in situ (DCIS) is a malignant, yet pre-invasive disease of the breast. While the majority of DCIS have low risk of recurrence, a subset of women with germline pathogenic variants (PV) in cancer predisposition genes are at increased risk for recurrence. Uptake of genetic te...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Lauren Turza, Leann A. Lovejoy, Clesson E. Turner, Craig D. Shriver, Rachel E. Ellsworth
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Frontiers Media S.A. 2022-08-01
Sarja:Frontiers in Oncology
Aiheet:
ductal carcinoma in situ
genetic testing
germline mutation
risk-reducing surgery
recurrence
Linkit:https://www.frontiersin.org/articles/10.3389/fonc.2022.918757/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.918757/full

Samankaltaisia teoksia